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Abstract
Background: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence
rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition of
Factor Xa in a Global trial versus ASA to prevenT Embolism in Embolic Stroke of Undetermined Source international
trial will compare the efficacy and safety of rivaroxaban, an oral factor Xa inhibitor, versus aspirin for secondary pre-
vention in patients with recent embolic strokes of undetermined source.
Main hypothesis: In patients with recent embolic strokes of undetermined source, rivaroxaban 15mg once daily will
reduce the risk of recurrent stroke (both ischemic and hemorrhagic) and systemic embolism (primary efficacy outcome)
compared with aspirin 100mg once daily.
Design: Double-blind, randomized trial in patients with embolic strokes of undetermined source, defined as nonlacunar
cryptogenic ischemic stroke, enrolled between seven days and six months from the qualifying stroke. The planned sample
size of 7000 participants will be recruited from approximately 480 sites in 31 countries between 2014 and 2017
and followed for a mean of about two years until at least 450 primary efficacy outcome events have occurred.
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The primary safety outcome is major bleeding. Two substudies assess (1) the relative effect of treatments on MRI-
determined covert brain infarcts and (2) the biological underpinnings of embolic strokes of undetermined source using
genomic and biomarker approaches.
Summary: The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus ASA to prevenT Embolism in
Embolic Stroke of Undetermined Source trial is evaluating the benefits and risks of rivaroxaban for secondary stroke
prevention in embolic strokes of undetermined source patients. Main results are anticipated in 2018.
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Introduction
Ischemic strokes traditionally classiﬁed as cryptogenic
remain frequent despite advances in the diagnostic tech-
niques to determine stroke etiology.1,2 Most nonlacu-
nar cryptogenic ischemic strokes are presumed due to
emboli, originating from a multitude of cardiac and
arterial sources or occasionally from venous thrombo-
embolism (i.e. via paradoxical embolism).1 Cryptogenic
conventionally denotes a stroke where high-risk sources
of embolism (such as atrial ﬁbrillation) are absent, but
many patients diagnosed with cryptogenic stroke are
found to have one or more potential embolic sources
if thoroughly evaluated, and it is often not possible to
be certain of the speciﬁc origin of the suspected embo-
lus.3,4 These observations have led to the construct of
embolic strokes of undetermined source (ESUS) in
order to deﬁne a cohort of patients that may respond
better to anticoagulation than antiplatelet therapy for
secondary stroke prevention.1 In brief, ESUS is
diagnosed when a nonlacunar ischemic stroke occurs
in a patient in whom subsequent investigations do not
show another speciﬁcally treatable underlying stroke
etiology, primarily >50% stenosis in a proximal extra-
cranial or intracranial artery, atrial ﬁbrillation, or other
major-risk cardioembolic source. A recent prospective
global registry reported that 16% of ischemic stroke
patients met criteria for ESUS (19% if stroke patients
who did not undergo the complete evaluation required
for diagnosis were excluded).5
Supported by their eﬃcacy for prevention of embolic
stroke in atrial ﬁbrillation patients,6,7 anticoagulants have
been hypothesized to be more eﬃcacious than antiplatelet
drugs for secondary prevention following ESUS.1 The
most promising anticoagulants for the prevention of
embolic stroke and systemic embolism are the nonvitamin
K antagonist direct oral anticoagulants (DOACs).
Compared with warfarin and its congeners, DOACs
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carry a lower risk of intracranial hemorrhage, the most
devastating complication of anticoagulation.8 The ESUS
construct combined with the availability of eﬃcacious
and safe DOACs has prompted the initiation of several
randomized trials aimed at reducing recurrent stroke in
ESUS patients.9–11 Here, the design highlights and key
protocol issues of the New Approach riVaroxaban
Inhibition of Factor Xa in a Global trial versus ASA to
prevenT Embolism in Embolic Stroke of Undetermined
Source (NAVIGATE ESUS) trial are presented.
Design
Overview and timelines
NAVIGATE ESUS (Clinicaltrials.gov.NCT02313909)
is an international, double-blinded, randomized phase
III trial comparing rivaroxaban 15mg once daily
(immediate-release, ﬁlm-coated tablets) with aspirin
(enteric-coated) 100mg once daily, both to be taken
with food, in patients with recent ESUS (Figure 1).
Matching placebos will be used in this double-blinded
trial. The primary hypothesis is that rivaroxaban is
superior to aspirin for reducing the risk of recurrent
stroke and systemic embolism (primary eﬃcacy out-
come). Seven thousand patients will be enrolled to
detect a 30% reduction in primary eﬃcacy outcome
events with 90% power by assignment to rivaroxaban
based on an estimated rate of 3.8% per year among
aspirin-assigned patients.1 Participants will be rando-
mized between seven days and six months following
the qualifying ESUS at about 480 sites in 31 countries
(Figure 2). Patient recruitment began in December 2014
and is anticipated to ﬁnish in 2017. Mean patient
follow-up is expected to be about two years, but the
study will continue until at least 450 participants have
experienced a primary eﬃcacy outcome event. The
main results are anticipated to be available in 2018.
Figure 2. Countries participating in NAVIGATE ESUS.
Figure 1. NAVIGATE ESUS design overview.
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Study population
Screening ischemic stroke patients for participation is
based on ﬁve key eligibility criteria as summarized in
Table 1. In short, patients 50 years old with nonlacu-
nar ischemic stroke visualized by neuroimaging and
without a clear etiology are included for whom most
current guidelines recommend antiplatelet therapy for
secondary prevention (Figure 3). After the qualifying
stroke, at least 20 h of cardiac rhythm monitoring is
required to exclude atrial ﬁbrillation lasting >6min,
although investigators can choose to monitor for
longer periods per local clinical practice standards.
Intracranial arterial imaging is not required, but if
done, the presence of >50% intracranial atherosclerotic
stenosis supplying the ischemic area excludes participa-
tion. Patients with left ventricular systolic dysfunction
of any severity, patent foramen ovale (PFO), and
all types of aortic arch plaque are eligible if anticoagu-
lation (or PFO closure) is not planned and potential
randomization to aspirin is acceptable to local investi-
gators. Transthoracic echocardiography is mandatory,
with transesophageal echocardiography (TEE) optional
and an acceptable substitute, with intracardiac throm-
bus detected by either technique an exclusion criterion.
Patients with carotid artery atherosclerotic plaques
causing 50% stenosis are eligible regardless of ulcer-
ation or other features. The outer time limit (i.e. six
months) between qualifying stroke and randomization
was chosen because the temporal pattern of recurrent
stroke is not known for ESUS patients
and it was deemed worthwhile to determine the abso-
lute beneﬁts of anticoagulation for ESUS patients who
are identiﬁed after the acute phase due to diagnostic
delays.
Exclusion criteria include severely disabling stroke
(modiﬁed Rankin score 4 at screening), the presence
or plan to insert an implantable ECG loop recorder,
speciﬁc indication for chronic anticoagulation or for
chronic antiplatelet therapy, ongoing regular use of
conventional nonsteroidal anti-inﬂammatory drugs,
previous nontraumatic intracranial hemorrhage (an
exception is hemorrhagic transformation of ischemic
stroke), and required use of strong inhibitors of
both cytochrome P450 isoenzyme 3A4 (CYP3A4) and
P-glycoprotein (e.g. protease inhibitors and several
azole-antimycotic agents) (Table 2).
Patients are randomly allocated by an interactive
voice/web response system to either rivaroxaban or
aspirin in a 1:1 ratio, with the block size sequestered
until the end of recruitment. Randomization is strati-
ﬁed by country and by age <60 and 60 years.
Follow-up
Participants return for outpatient oﬃce visits at one,
six, and 12 months and then every six months until a
Table 1. Inclusion criteria.
Embolic stroke of undetermined source (ESUS)a between seven daysb and six months:
1. Ischemic stroke visualized by CT or MRI that is not lacunarc
2. Absence of extracranial and, if intracranial imaging performed, intracranial atherosclerosis causing >50% luminal stenosis of arteries
supplying the area of ischemiad
3. No atrial fibrillation by history, ECG, or after >20 h of cardiac rhythm monitoringe
4. No intracardiac thrombus by echocardiography
5. No other specific cause of ischemic stroke identified (e.g. high-risk cardiac sourcef usually requiring anticoagulation, cardiac tumor,
arteritis, dissection, migraine/vasospasm, cerebral venous thrombosis, drug abuse)
Age 50 yearsg
Ability and willingness to provide written informed consent
CT: computed tomography; ECG: electrocardiogram; MRI: magnetic resonance imaging.
aCriteria for ESUS contrast with the original definition proposed by the Cryptogenic Stroke/ESUS International Working Group in three main ways (1):
intracranial arterial imaging is not required, intracranial arterial occlusion does not exclude participation if diagnosed as embolic, and exclusion based
on echocardiography is limited to intracardiac thrombus.
bPatients with minor stroke (NIH stroke scale score 3) can be entered as soon as three days after onset and not before 10 days in case of
hemorrhagic transformation or intravenous thrombolysis therapy and unless repeat CT or MRI performed before randomization documents the
absence of new or extension of bleeding.
cLacunar defined as an infarct 1.5 cm in largest dimension involving any subcortical area of the cerebral hemispheres, pons, and midbrain.
dArterial imaging includes sonography (including transcranial Doppler) or CT, MR, or digital subtraction angiography of the relevant arteries.
eCardiac rhythm monitoring using automated rhythm detection strongly encouraged, but cardiac telemetry carried out in an inpatient stroke unit
acceptable.
fMechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, severe mitral stenosis, or infective endocarditis.
gPatients between age 50 and 59 must have one or more additional stroke risk factors (hypertension, tobacco smoking at time of qualifying stroke,
ischemic stroke or TIA prior to qualifying stroke, heart failure, or diabetes); patients age 18–50 years with additional risk factors were eligible prior to
the protocol amendment of late 2015.
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common end-study date. At three months, participants
are contacted by telephone, and a telephone contact is
done one month after the end-of-treatment visit.
Participants are assessed for the occurrence of safety
and eﬃcacy events, adherence, adverse events and
vital signs, and quality of life, functional status and
cognitive function are recorded. Adherence to assigned
therapy is assessed by interview and pill counts at each
visit. Low-dose (100mg daily) aspirin in addition to
study-assigned therapy is permitted if a new indication
develops during follow-up (e.g. stable coronary artery
disease), but dual antiplatelet therapy mandates cessa-
tion of study drug for the duration of use.
Outcome events
The primary eﬃcacy outcome is time to recurrent
stroke (ischemic, hemorrhagic, and undeﬁned stroke,
including TIAs with positive neuroimaging) or systemic
embolism. This outcome was chosen in part to align
with trials demonstrating a substantial reduction in
the risk of embolic events by DOACs in atrial ﬁbrilla-
tion patients. Secondary eﬃcacy outcomes are outlined
in Table 3. The primary safety outcome is major bleed-
ing according to the criteria of the International Society
of Thrombosis and Haemostasis.12 We anticipate that
the annual rate of intracerebral hemorrhage will be
relatively low (<0.4%/yr) due to prohibition of con-
comitant dual antiplatelet therapy, exclusion of lacunar
strokes as qualifying events, and delayed initiation of
anticoagulation for a least seven days after the qualify-
ing stroke, and be equal in both treatment arms.
Extracranial major hemorrhage is anticipated to be
increased among those assigned rivaroxaban versus
aspirin (2%/year versus 1%/year, respectively).13,14
Statistical analysis plan
The primary eﬃcacy analyses will be based on the
intent-to-treat population. Rivaroxaban-assigned
patients will be compared with the aspirin control
group using a log–rank test. Kaplan–Meier estimates
will be used to plot the cumulative incidence risk over
Figure 3. Conceptual scheme for screening to identify ESUS
patients. Prior to diagnostic testing, approximately 15% of
strokes would be ESUS. With each additional step in screening,
the probability increases toward 100%.5 *After excluding less
uncommon stroke etiologies (e.g. dissections).
Table 2. Key exclusion criteria.
1. Severely disabling stroke (modified Rankin score 4 at
screening)
2. Patent foramen ovale with plans for closure
3. Known serious infection or inflammatory disease that may
be the cause of stroke
4. Patient has or is intended to receive an implantable ECG
loop recorder
5. Indication for chronic anticoagulation
6. Indication for chronic antiplatelet therapy
7. Active bleeding/major bleeding within last six months/
previous nontraumatic intracranial hemorrhage
(any type, ever)/high risk for serious bleeding
8. Hepatic disease associated with coagulopathy
9. Renal disease with estimated GFR< 30ml/min/1.73m2
10. Life expectancy less than six months
11. Use of strong inhibitors of both cytochrome P450
isoenzyme 3A4 (CYP3A4) and P-glycoprotein (e.g. protease
inhibitors and several azole-antimycotic agents)
12. Female of childbearing potential who is not surgically sterile
or who is sexually active and not using reliable contraception
13. Chronic, regular use of a conventional nonsteroidal
anti-inflammatory drug
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time. Risk reduction will be estimated with the Cox
proportional hazards model. Secondary eﬃcacy out-
comes will be analyzed using similar methods as for
the primary eﬃcacy analysis, with testing performed
in hierarchical order to control the global type 1 error
level (Table 3). The statistical analysis plan includes
several prespeciﬁed subgroup analyses based on age,
sex, global region, and time from index stroke to ran-
domization of <30 days, 31 days to 3 months, and >3
months.
Study development and committees
The trial coprincipal investigators from the Population
Health Research Institute (RGH, SJC) initially pro-
posed the trial to Bayer Pharma AG (SDB). The
Steering Committee is responsible for the scientiﬁc lead-
ership and consists of the national leaders (n¼ 32) of
each participating country, the coprincipal investiga-
tors, sponsor representatives, and additional experts
in thrombosis and clinical trials. The Publications
Committee approves all manuscripts prior to submis-
sion and consists of four national leaders (rotating
annually), the coprincipal investigators, and a sponsor
representative. Sponsor representatives (who comprise
<15% of these two committees) have voting rights.
Outcome event veriﬁcation is overseen by a central
Adjudication Committee that will assess whether
reported outcome events meet study criteria.
An independent Data Monitoring Committee moni-
tors participant safety on an ongoing basis and may
recommend modiﬁcation of the study protocol in case
unexpected safety concerns arise or may terminate the
study for safety concerns that are not oﬀset by beneﬁts
related to stroke reduction. Two formal interim ana-
lyses will occur when approximately 50 and 67% of
primary eﬃcacy outcome events have accrued, and
the trial will be stopped for overwhelming eﬃcacy by
one treatment relative to the other if not mitigated by
safety issues.
Two substudies
The primary objective of the MIND MRI Substudy is
to determine the eﬀect of rivaroxaban versus aspirin on
MRI-deﬁned clinically silent (or covert) brain infarcts
and clinical ischemic strokes. Covert infarcts are neither
asymptomatic nor benign and result in considerable
morbidity including cognitive decline, loss of independ-
ence, gait impairment, and falls. While stroke recur-
rence increases the likelihood of dementia, poststroke
cognitive decline often occurs in the absence of clinical
recurrence. The mechanism is thought to be either a
manifestation of the increasing vascular burden or an
interaction between subclinical ischemia and coexisting
neurodegenerative pathology, principally Alzheimer’s
disease. Therapies aimed at interrupting the accumulat-
ing vascular pathology and its consequences may
improve the cognitive and functional trajectory of
ESUS patients.
The incidence of covert brain infarcts is expected to
exceed recurrent clinical ischemic strokes, but owing
to the possible heterogeneous pathogenesis of these
lesions, covert infarcts may be less sensitive to anti-
coagulants regarding prevention. About 1000 partici-
pants will undergo brain MRI using a standardized
acquisition protocol near the time of randomization
that will be repeated near study end. MRIs will be inter-
preted at a core MRI facility by experts unaware of
treatment assignment.
The Biomarker, Genetics, Gene Expression
Substudy will collect plasma, RNA, and DNA samples
from up to 3000 participants for exploratory analyses
aimed at establishing whether ESUS is a distinct clinical
entity or the result of multiple unrelated causes
that have in common a propensity for thrombosis.
The substudy will integrate biomarker information,
comprehensive genomics characterization, and gene
expression (including miRNA) data to identify path-
ways linked to ESUS and stroke recurrence.
Integration of these approaches has the potential to
be more revealing than the use of any one alone.
Anticipated analyses include the predictive value of
D-dimer for recurrent stroke, NT-proBNP levels as
Table 3. Trial outcome events.
Primary efficacy outcome:
 Stroke (ischemic, hemorrhagic, and undefined stroke,
TIA with positive neuroimaging) and systemic embolism
Secondary efficacy outcomes:a
 Cardiovascular death (including death due to all types of
hemorrhage), recurrent stroke, systemic embolism, and
myocardial infarction
 All-cause mortality
 Individual components of the primary and secondary efficacy
outcomes (stroke, cardiovascular death, and myocardial
infarction) as well as
 Recurrent ischemic stroke (including TIA with positive
neuroimaging)
 Disabling/fatal stroke (modified Rankin score 4)
at 90 days after recurrence
Primary safety outcome:
 Major bleeding meeting ISTH criteria12
Secondary safety outcomes:
 Life-threatening bleeding
 Clinically relevant nonmajor bleeding
 Intracranial hemorrhage
aListed in the order of sequential testing.
ISTH: International Society on Thrombosis and Haemostasis;
TIA: transient ischemic attack.
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predicting atrial ﬁbrillation during follow-up, and
several as yet undeﬁned, exploratory biomarkers for
predicting clinical events.
Design issues
Choice of aspirin as the control antiplatelet therapy
Aspirin is the best characterized and most widely used
antiplatelet therapy for secondary stroke prevention.
Most experts believe that there is no compelling evi-
dence that other antiplatelet agents oﬀer important
beneﬁts over aspirin, and hence many major guidelines
include aspirin as acceptable chronic antiplatelet ther-
apy for secondary stroke prevention, including for
patients with cryptogenic ischemic strokes.15–17
However, in some countries, aspirin monotherapy is
not the preferred antiplatelet therapy for secondary
stroke prevention.18 If investigators were allowed to
choose the antiplatelet comparator and dose based on
local preference, a double-blind comparison with rivar-
oxaban would not be feasible, and it was elected to
choose a single antiplatelet comparator. For ESUS
patients, there are no existing data about relative eﬃ-
cacy of diﬀerent antiplatelet therapies. Hence, aspirin is
the most reasonable choice for the antiplatelet control
arm of NAVIGATE ESUS and in-line with current
global practice.5,18
Choice of 15mg once daily dose of rivaroxaban
The selection of a dose of anticoagulant for a new indi-
cation often involves a phase 2 dose-ranging study.
However, such a study was not considered feasible
due to the relatively low rate of recurrent stroke in
ESUS patients and the absence of an established surro-
gate biomarker. Consequently, the dosage was extrapo-
lated from clinical evidence on the use of rivaroxaban
in other patient populations. Rivaroxaban 20mg daily
(15mg daily for those with an estimated creatinine
clearance between 30 and 49ml/min) was eﬃcacious
and safe in patients with atrial ﬁbrillation, in whom
embolism is the dominant cause of stroke.19
Rivaroxaban 15mg daily dose appears to be eﬃcacious
for stroke prevention in Japanese patients with atrial
ﬁbrillation.20 Due to concern about a potentially higher
rate of intracerebral hemorrhage in patients with recent
ischemic stroke, a dosage of 15mg once daily in ESUS
patients, without dose reduction for moderate renal
impairment, was deemed appropriate. Modeling data
show an overlap of exposure (i.e. of rivaroxaban
plasma concentrations over time) for the 15 and
20mg doses.21 For this patient population, rivaroxaban
15mg daily was chosen to optimally balance eﬃcacy
with safety.
Screening participants for covert
paroxysmal atrial fibrillation
When the trial was designed in 2013–2014, the
approach to detection of atrial ﬁbrillation at many
stroke centers was an ECG at hospital admission and
24 h of inpatient telemetry or Holter monitoring.5,22 In
mid-2014, two inﬂuential studies reported that brief
episodes (several minutes) of previously unrecognized
atrial ﬁbrillation could be detected in 10–20%
of patients with cryptogenic ischemic stroke if the
duration of cardiac monitoring was prolonged to 30
days.23,24 However, it is unknown whether brief
(6min) episodes of atrial ﬁbrillation detected weeks
or months after stroke identify patients who beneﬁt
from anticoagulation. Further, short episodes of atrial
ﬁbrillation are not necessarily temporally associated
with stroke risk, raising further doubt about their rele-
vance to the pathogenesis of stroke.25
For NAVIGATE ESUS eligibility, screening for
covert paroxysmal atrial ﬁbrillation with 20h of car-
diac rhythm monitoring is required, with episodes
>6min duration mandating exclusion based on the
ASSERT trial.26 Sites are permitted to monitor for
longer periods (e.g. 7–30 days) based on local clinical
practice, but monitoring must be completed prior to ran-
domization. Randomization of patients undergoing pro-
longed (e.g. months to years) cardiac rhythm monitoring
using implanted recorders is an exclusion criterion
because of the uncertain implications of subgroup ana-
lysis in those with implanted monitoring devices and the
likelihood of cross-over based on current enthusiasm in
some countries for the use of anticoagulants if even brief
episodes of atrial ﬁbrillation are detected.
If NAVIGATE ESUS results demonstrate a reduction
in recurrent ischemic stroke with anticoagulation, could
this overall result be driven by a large treatment eﬀect
among a subgroup of subjects with covert paroxysmal
atrial ﬁbrillation?While this is unlikely based on predicted
frequencies, this possibility will be assessed by routine
clinical screening to determine if atrial ﬁbrillation is pre-
sent at the time of primary eﬃcacy events and comparing
the frequency of atrial ﬁbrillation between treatment
arms. Further, if rivaroxaban shows superior eﬃcacy
versus aspirin and is relatively safe for ESUS patients, it
will challenge the need for prolonged cardiac rhythm
monitoring for most patients with cryptogenic stroke.
Relative effects of rivaroxaban versus aspirin
on different embolic sources
ESUS includes multiple sources (cardiac, arterial, para-
doxical). Are diﬀerent embolic sources likely to respond
similarly to rivaroxaban versus aspirin? Clinical trials
have not shown a beneﬁt of anticoagulation over
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antiplatelet therapy for secondary prevention of stroke
due to arterial sources (including intracranial stenosis
and aortic arch atheroma), but subgroup analyses sup-
port the biologic plausibility if a consistent anticoagu-
lant eﬀect can be maintained.27–29 Further, often two or
more potential embolic sources are detected in individ-
ual ESUS patients, and the speciﬁc culprit cannot be
identiﬁed, so that it is pragmatic to assess the relative
eﬀect of antithrombotic therapies among all ESUS
patients. A series of exploratory subgroup analyses
will examine recurrent stroke rates and response to
anticoagulation associated with individual potential
embolic sources as well as the presence of prothrombo-
tic disorders (e.g. active cancer).30,31
Should TEE be required for eligibility?
Minor-risk embolic sources are more frequently
detected using TEE than with precordial echocardiog-
raphy,32 and TEE is sometimes recommended routinely
for young patients with cryptogenic stroke. However,
global surveys indicate that TEE is infrequently done
in routine clinical practice,5,22 and with uncertain
evidence-based management implications.33 While it
would be ideal to more accurately characterize minor-
risk embolic sources, mandating TEE (mildly invasive
and costly) for trial eligibility would severely restrict the
number of participating sites and bias recruitment to
patients willing to undergo this procedure.
Discussion
Although an embolic etiology for most cryptogenic ische-
mic strokes was proposed more than two decades ago,4
there has been little progress in secondary stroke preven-
tion for this large fraction of patients with ischemic stroke.
Among such patients meeting criteria for ESUS, we antici-
pate that rivaroxaban will be associated with a reduced risk
of recurrent embolic events, similar rates of intracranial
hemorrhage, and only modestly increased (and potentially
acceptable) rates of major extracranial hemorrhage relative
to aspirin. NAVIGATE ESUS is a multinational, rando-
mized, double-blind, superiority trial comparing antith-
rombotic therapies for secondary stroke prevention in a
well-deﬁned cohort of patients with nonlacunar crypto-
genic stroke with embolic features. In order to be widely
applicable globally, the trial is designed pragmatically (e.g.
intracranial imaging is not required because this would
exclude participation of many sites where this is not stand-
ard practice, and the duration of cardiac rhythm monitor-
ing over 20h is ﬂexible). Anticipated subgroup analyses
comparing rivaroxaban with aspirin for stroke prevention
in participants with PFO, left ventricular systolic dysfunc-
tion, active cancer, or nonstenotic atherosclerotic plaques
in the aorta, carotid arteries, and intracranial arteries are
likely to be underpowered but still of considerable clinical
interest. NAVIGATE ESUS is likely to be a landmark
clinical trial impacting clinical management of large num-
bers of patients with cryptogenic ischemic stroke attributed
to embolism.
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